WO2008010061A3 - 3-azabicyclo[3.1.0]hexanes ligands du récepteur vanilloïde, compositions pharmaceutiques les contenant et leurs procédés de préparation - Google Patents
3-azabicyclo[3.1.0]hexanes ligands du récepteur vanilloïde, compositions pharmaceutiques les contenant et leurs procédés de préparation Download PDFInfo
- Publication number
- WO2008010061A3 WO2008010061A3 PCT/IB2007/002002 IB2007002002W WO2008010061A3 WO 2008010061 A3 WO2008010061 A3 WO 2008010061A3 IB 2007002002 W IB2007002002 W IB 2007002002W WO 2008010061 A3 WO2008010061 A3 WO 2008010061A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- azabicyclo
- processes
- hexane
- receptor ligands
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des dérivés substitués de 3-azabicyclo[3.1.0]hexane utilisables en tant que ligands du récepteur vanilloïde, ainsi que des procédés qui les utilisent pour traiter des maladies, des affections et/ou des troubles induits par les récepteurs vanilloïdes et des procédés permettant de les préparer.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1136/MUM/2006 | 2006-07-17 | ||
IN1136MU2006 | 2006-07-17 | ||
US83556006P | 2006-08-03 | 2006-08-03 | |
US60/835,560 | 2006-08-03 | ||
IN381/MUM/2007 | 2007-02-27 | ||
IN381MU2007 | 2007-02-27 | ||
US89367507P | 2007-03-08 | 2007-03-08 | |
US60/893,675 | 2007-03-08 | ||
US94771507P | 2007-07-03 | 2007-07-03 | |
US60/947,715 | 2007-07-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008010061A2 WO2008010061A2 (fr) | 2008-01-24 |
WO2008010061A3 true WO2008010061A3 (fr) | 2008-04-17 |
Family
ID=38928004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2007/002002 WO2008010061A2 (fr) | 2006-07-17 | 2007-07-16 | 3-azabicyclo[3.1.0]hexanes ligands du récepteur vanilloïde, compositions pharmaceutiques les contenant et leurs procédés de préparation |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR061905A1 (fr) |
WO (1) | WO2008010061A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2008002053A1 (es) | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
AR067536A1 (es) | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
WO2009034433A2 (fr) * | 2007-09-10 | 2009-03-19 | Glenmark Pharmaceuticals, S.A. | Dérivés de 3-azabicyclo [3.1.0] hexane utilisés comme ligands des récepteurs vanilloïdes |
WO2009090548A2 (fr) * | 2008-01-17 | 2009-07-23 | Glenmark Pharmaceuticals, S.A. | Dérivés de 3-azabicyclo[3.1.0]hexane utilisés comme ligands des récepteurs vanilloïdes |
CA2806634A1 (fr) * | 2010-08-20 | 2012-02-23 | Gruenenthal Gmbh | Derives de carboxamide et d'uree cycliques substitues en tant que ligands du recepteur vanilloide |
JP6774403B2 (ja) * | 2014-06-12 | 2020-10-21 | アロサイト ファーマスーティカルズ アーゲー | 小分子lfa−1阻害薬 |
BR112021024108A2 (pt) | 2019-05-31 | 2022-03-22 | Ikena Oncology Inc | Inibidores de tead e usos dos mesmos |
MX2021014441A (es) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
AU2020365108A1 (en) | 2019-10-18 | 2022-04-21 | Atengen, Inc. | 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders |
RU2755206C1 (ru) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия и лекарственный препарат на его основе |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993018001A1 (fr) * | 1992-03-02 | 1993-09-16 | Pfizer Inc. | Preparation d'intermediaires dans la synthese d'antibiotiques a la quinoline |
US5475116A (en) * | 1994-04-29 | 1995-12-12 | Pfizer Inc. | Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones |
US6184380B1 (en) * | 1999-01-25 | 2001-02-06 | Pfizer Inc. | Process for preparing naphthyridones and intermediates |
US6194438B1 (en) * | 1998-12-02 | 2001-02-27 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one, and compositions and methods for inhibiting abnormal cell growth comprising said derivatives |
WO2002090326A1 (fr) * | 2001-05-02 | 2002-11-14 | Smithkline Beecham P.L.C. | Urees heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur vanilloide |
WO2004052857A1 (fr) * | 2002-12-10 | 2004-06-24 | Ranbaxy Laboratories Limited | Derives d'azabicyclo [3.1.0] hexane 3,6-disubstitues utilises comme antagonistes du recepteur muscarinique |
WO2004078749A1 (fr) * | 2003-03-06 | 2004-09-16 | Glaxo Group Limited | Derives d'uree heterocycliques pour le traitement de la douleur |
WO2005051390A1 (fr) * | 2003-10-29 | 2005-06-09 | Merck Sharp & Dohme Limited | Derives de 4-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide et composes associes modulant la fonction du recepteur vanilloide (vr1) pour le traitement de la douleur |
WO2007029086A2 (fr) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Derives de 3-azabicyclo[3.1.0]hexane en tant qu'inhibiteurs de la dipeptidyl peptidase-iv |
WO2007077508A2 (fr) * | 2005-12-30 | 2007-07-12 | Ranbaxy Laboratories Limited | Dérivés de bêta-aminoacides comme inhibiteurs de la dipeptidylpeptidase iv |
-
2007
- 2007-07-16 WO PCT/IB2007/002002 patent/WO2008010061A2/fr active Application Filing
- 2007-07-17 AR ARP070103179A patent/AR061905A1/es unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993018001A1 (fr) * | 1992-03-02 | 1993-09-16 | Pfizer Inc. | Preparation d'intermediaires dans la synthese d'antibiotiques a la quinoline |
US5475116A (en) * | 1994-04-29 | 1995-12-12 | Pfizer Inc. | Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones |
US6194438B1 (en) * | 1998-12-02 | 2001-02-27 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one, and compositions and methods for inhibiting abnormal cell growth comprising said derivatives |
US6184380B1 (en) * | 1999-01-25 | 2001-02-06 | Pfizer Inc. | Process for preparing naphthyridones and intermediates |
WO2002090326A1 (fr) * | 2001-05-02 | 2002-11-14 | Smithkline Beecham P.L.C. | Urees heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur vanilloide |
WO2004052857A1 (fr) * | 2002-12-10 | 2004-06-24 | Ranbaxy Laboratories Limited | Derives d'azabicyclo [3.1.0] hexane 3,6-disubstitues utilises comme antagonistes du recepteur muscarinique |
WO2004078749A1 (fr) * | 2003-03-06 | 2004-09-16 | Glaxo Group Limited | Derives d'uree heterocycliques pour le traitement de la douleur |
WO2005051390A1 (fr) * | 2003-10-29 | 2005-06-09 | Merck Sharp & Dohme Limited | Derives de 4-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide et composes associes modulant la fonction du recepteur vanilloide (vr1) pour le traitement de la douleur |
WO2007029086A2 (fr) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Derives de 3-azabicyclo[3.1.0]hexane en tant qu'inhibiteurs de la dipeptidyl peptidase-iv |
WO2007077508A2 (fr) * | 2005-12-30 | 2007-07-12 | Ranbaxy Laboratories Limited | Dérivés de bêta-aminoacides comme inhibiteurs de la dipeptidylpeptidase iv |
Non-Patent Citations (6)
Title |
---|
CHEM. EUROP. J., vol. 8, no. 16, 2002, pages 3789 - 3801 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002465472, Database accession no. BRN:8563110 * |
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002465473, Database accession no. BRN:9222926 * |
ELMAR VILSMAIER ET AL: "Reductive decyanation of N-protected 6-Amino-3-azabicyclo(3.1.0)hexan ecarbonitriles", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 54, no. 23, 1998, pages 6403 - 6414, XP002081309, ISSN: 0040-4020 * |
GILLASPY M L ET AL: "A Simple Method for the Formation of Cyclopropylamines: The First Synthesis of Tricyclopropylamine", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 36, no. 41, 9 October 1995 (1995-10-09), pages 7399 - 7402, XP004027008, ISSN: 0040-4039 * |
J. CHEM. SOC. PERKIN TRANS., vol. 10, 2000, pages 1615 - 1622 * |
Also Published As
Publication number | Publication date |
---|---|
AR061905A1 (es) | 2008-10-01 |
WO2008010061A2 (fr) | 2008-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008010061A3 (fr) | 3-azabicyclo[3.1.0]hexanes ligands du récepteur vanilloïde, compositions pharmaceutiques les contenant et leurs procédés de préparation | |
WO2009090548A3 (fr) | Dérivés de 3-azabicyclo[3.1.0]hexane utilisés comme ligands des récepteurs vanilloïdes | |
WO2010109334A3 (fr) | Dérivés de thiénopyrimidinedione comme modulateurs de trpa1 | |
TW200801013A (en) | Substituted benzofused derivatives and their use as vanilloid receptor ligands | |
MX2013006634A (es) | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1. | |
WO2008152099A3 (fr) | Aryl/hétarylamides en tant que modulateurs du récepteur ep2 | |
WO2010048332A3 (fr) | Composés de traitement de maladies et troubles ophtalmiques | |
WO2007052023A3 (fr) | Composes | |
WO2009111700A3 (fr) | Oxadiazoanthracènes pour le traitement du diabète | |
WO2012009009A3 (fr) | Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate | |
WO2006037982A3 (fr) | Nouveaux composes | |
TW200612892A (en) | Novel compounds | |
WO2008152093A3 (fr) | Diaminopyrimidines en tant que modulateurs du récepteur ep2 | |
WO2008059339A3 (fr) | Dérivés d'isoquinoline comme modulateurs des récepteurs vanilloïdes | |
WO2007020213A3 (fr) | Derives de thiazolylpiperidines | |
WO2007079163A3 (fr) | Antagonistes du recepteur de la prokineticine 1 | |
WO2006067428A3 (fr) | Agents therapeutiques | |
MX2007002393A (es) | Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6). | |
WO2008005908A3 (fr) | Dérivés de pyridoïmidazole | |
WO2009104021A3 (fr) | Nouveaux polymorphes et procédés de préparation | |
MY143581A (en) | Carboxamide derivatives as muscarinic receptor antagonists | |
WO2007041076A3 (fr) | Derives de 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one utilises en tant qu'agonistes du recepteur rxr pour le traitement de la dyslipidemie, de l'hypercholesterolemie et du diabete | |
WO2010054024A3 (fr) | Nouveaux composés en tant que ligands des récepteurs cannabinoïdes | |
WO2011132051A3 (fr) | Composés tricycliques en tant qu'inhibiteurs de la phosphodiestérase-10 | |
WO2009038385A3 (fr) | Nouveaux composés présentant des squelettes d'indazole, méthodes de préparation de ceux-ci et composition pharmaceutique les contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07804611 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07804611 Country of ref document: EP Kind code of ref document: A2 |